ARTMS Inc. is pleased to announce the successful acquisition of Telix Pharmaceuticals Limited. This acquisition is set to enhance the supply chain and regulatory control of producing key isotopes at ARTMS, further strengthening its vertical integration in the manufacturing space. The acquisition will enable ARTMS to efficiently and cost-effectively support the large-scale production of medical isotopes and collaborate with other radiopharmaceutical companies to ensure the availability of these critical isotopes to patients. Additionally, ARTMS’s advanced cyclotron technology will facilitate Telix's production of future important commercial alpha-emitting therapeutic isotopes including radium-225 (225Ac) and astatine-211 (211At), allowing for immediate commercial use.